Summary of COVID-19 belnacasan studies

1. Wortmann et al., A Proof of Concept, Randomized, Double-blind, Placebo-controlled Trial of Orally Administered Belnacasan Tablets for the Treatment of Mild to Moderate COVID-19

40 patient belnacasan early treatment RCT: 34% slower recovery (p=0.29).
RCT 40 outpatients in the USA, showing no significant difference in recovery with belnacasan treatment.
Oct 2022, NCT05164120, https://clinicaltrials.gov/study/NCT05164120, https://c19p.org/wortmann